The UK’s Technology Strategy Board has awarded Domainex a £250,000 grant to develop of a new drug to treat several common cancers.

The drug will act by inhibiting two protein kinases, TBK1 and IKKe, which will suppress certain cancer cell lines from growing.

The aim of the project is to identify a drug candidate that is effective in disease models and would be orally well-absorbed by humans.

Domainex research director Trevor Perrior said that the novel mode of action will allow the treatment of patients with drug-resistant, triple-negative tumours.

The marketing of the new drug will be done in partnership with a large pharmaceutical company that has the ability to conduct drug trials, Domainex said.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.